Day 3 Program

Poster Spotlight 13: Triple Negative Breast Cancer

Day 3: December 10, 2026

7:00 AM–8:30 AM CST

Hemisfair 1-2

Session Details

Moderator

Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

PS13-1

Phase 1a/1b dose-escalation and -expansion study of BG-C9074 monotherapy in advanced solid tumors: preliminary data from patients with previously treated triple-negative breast cancer (TNBC)

Binghe Xu, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

PS13-2

Iparomlimab and tuvonralimab (QL1706)plus nab-paclitaxel , with or without bevacizumab as first-line treatment for recurrent or metastatic triple-negative breast cancer (QUEEN-NATURE): a multicenter, two-arm phase II trial

Hong-Xia Wang, Fudan University Shanghai Cancer Center, shang hai, China

PS13-3

Phase 1 Study of ASTX727 (decitabine and cedazuridine) in combination with paclitaxel and pembrolizumab for pre-treated metastatic triple-negative breast cancer (NCI Protocol #10546)

Roberto A Leon-Ferre, Mayo Clinic, Rochester, MN

PS13-4

Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy.

Hatem Soliman, Moffitt Cancer Center, Tampa, FL

PS13-5

Initial clinical results from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR positive/HER2 negative metastatic breast cancer

Kevin Chin, Marengo Therapeutics, Cambridge, MA

PS13-6

Discussant

Laura Huppert, University of California San Francisco, San Francisco, CA

PS13-7

Matching-adjusted indirect comparison (MAIC) of sacituzumab govitecan (SG) from ASCENT-03 vs chemotherapy from KEYNOTE-355 in participants with previously untreated advanced triple-negative breast cancer (TNBC)

Adam Brufsky, UPMC Magee-Womens Hospital, Pittsburgh, PA

PS13-8

Matching-adjusted indirect comparison (MAIC) of first-line (1L) sacituzumab govitecan (SG) plus pembrolizumab (pembro) from ASCENT-04/KEYNOTE-D19 vs chemotherapy (chemo) plus pembro from KEYNOTE-355 in participants with PD-L1+ metastatic triple-negative breast cancer (mTNBC)

Clinton Yam, The University of Texas MD Anderson Cancer Center, Houston, TX

PS13-9

Retrospective real-world cohort study of clinical outcomes in patients with recurrent metastatic triple-negative breast cancer (TNBC) who received immunotherapy in the early-stage setting

Tiffany A. Traina, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY

PS13-10

Immune profile score (IPS) to stratify outcomes in patients with metastatic triple negative breast cancer (mTNBC) treated with immune checkpoint inhibitors (ICIs)

Irene M Kang, City of Hope, Irvine, CA

PS13-11

Sacituzumab Govitecan outcomes according to phenotype changes at metastatic re-biopsy: a real-world analysis of patients with and without an initial triple-negative breast cancer diagnosis

Roberta Caputo, Istituto Nazionale Tumori, IRCCS, “Fondazione G. Pascale", Naples, Italy

PS13-13

Discussant

Irene Kang